Close

TS-IL15 SA Anti-PMEL (XW-745) BBζ CAR (XS-0822-YF10188)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The vector of anti-Human PMEL chimeric antigen receptor (CAR) is constructed for the engineering of T cells. The receptor construction is 7H-YB-IL15 SA-EF1a-scFv-41BB-CD3ζ. 7H-YB means seven repeats of the HSE motif 5'-nGAAnnTTCnnGAAn-3' upstream of the human synthetic core promoter (YB). 7H-YB is a technology for photothermal control of T cell therapies.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • PMEL
  • Targeting Diseases
  • Melanoma
  • Generation
  • 2nd-generation CAR
  • Vector Name
  • pCDCAR1
  • Vector Length
  • ~8kb
  • Vector Type
  • Lentiviral vector
  • Receptor Construction
  • 7H-YB-IL15 SA-EF1a-scFv-41BB-CD3ζ

Target

  • Clone
  • XW-745
  • Host
  • Mouse
  • Target Species
  • Human
  • Gene Name
  • PMEL
  • Synonyms
  • PMEL; premelanosome protein; P1; SI; SIL; ME20; P100; SILV; ME20M; gp100; ME20-M; PMEL17; D12S53E; melanocyte protein PMEL; melanocyte protein mel 17; silver; mouse; homolog of; melanocyte protein Pmel 17; melanosomal matrix protein17; silver locus protein homolog; melanoma-associated ME20 antigen; melanocytes lineage-specific antigen GP100
  • Introduction
  • This gene encodes a melanocyte-specific type I transmembrane glycoprotein. The encoded protein is enriched in melanosomes, which are the melanin-producing organelles in melanocytes, and plays an essential role in the structural organization of premelanosomes. This protein is involved in generating internal matrix fibers that define the transition from Stage I to Stage II melanosomes. This protein undergoes a complex pattern of prosttranslational processing and modification that is essential to the proper functioning of the protein. A secreted form of this protein that is released by proteolytic ectodomain shedding may be used as a melanoma-specific serum marker. Alternate splicing results in multiple transcript variants.

Customize Your CAR Products

Cannot find the desired product? Don't worry, just try our online CAR and CAR cell customizing system, which offers full options to meet all unique needs, including but not limited to conventional or unconventional CAR constructs, as well as a variety of vectors and cells. The customization process can be completed with just a few simple clicks, please feel free to try it out.
CAR and CAR Cell Customizing System

Customer Reviews and Q&As

There are currently no customer reviews or questions for TS-IL15 SA Anti-Human PMEL scFv (XW-745) 41BB-CD3ζ CAR, pCDCAR1 (XS-0822-YF10188). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.